Fundraising Overview - The company raised a total of RMB 717 million from the issuance of 30 million shares at RMB 23.90 per share, with a net amount of RMB 648.33 million after deducting issuance costs [1] - As of June 30, 2025, the company had a remaining balance of RMB 7.30 million in its fundraising account [3] Fund Management - The company has established a management system for fundraising in accordance with regulatory guidelines to ensure proper use and protection of investor rights [1] - A tripartite supervision agreement was signed with the underwriter and banks to ensure the funds are used specifically for their intended purposes [2][3] Fund Utilization - The company completed the investment projects related to the expansion of microbial oil and polyunsaturated fatty acid microencapsulation production lines in 2023, with final payments made during the reporting period [4][5] - The research center construction project has fully utilized the committed fundraising amount, with excess funding derived from interest income [4][8] Financial Management - The company has not used any excess fundraising to permanently supplement working capital or repay bank loans during the reporting period [5][6] - The board approved the temporary use of up to RMB 12 million of idle funds for cash management, ensuring it does not affect ongoing projects [5] Compliance and Reporting - The company has adhered to all relevant laws and regulations regarding the use of fundraising and has disclosed the usage status in a timely manner [7]